^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A*01

    i
    Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
    Entrez ID:
    3105
    Related biomarkers:
    Expression
    Mutation
    Others
    10ms
    Patient-specific HLA-I subtypes predict response to immune checkpoint blockade. (PubMed, Oncoimmunology)
    No significant associations were observed between HLA-A subtypes and the incidence of immune-related adverse effects. HLA genotyping should be incorporated early in the diagnostic work-up of patients with solid cancers as a predictive and selective biomarker.
    Journal • Checkpoint inhibition
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*01
    1year
    HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy. (PubMed, Cancers (Basel))
    The absence of association between genomic HLA-I/-II homozygosity and clinical outcome among patients with advanced NSCLC treated with pembrolizumab in combination with chemotherapy might reflect a diminished role for HLA molecules among patients with low or no PD-L1. HLA-A01 and HLA-B27 might have a role in predicting clinical outcomes among this cohort of patients. Further studies are needed to explore biomarkers for this group of patients.
    Clinical data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    HLA-A*01
    |
    Keytruda (pembrolizumab)